Bold Therapeutics is a clinical-stage biotech company that was founded in 2018 by a team of biopharma industry veterans to develop and commercialize BOLD-100, a first-in-class anti-resistance therapeutic.
BOLD-100, a ruthenium-based small molecule therapeutic, significantly enhances the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival and proliferation pathway.
Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
Bold Therapeutics' lead development candidate is BOLD-100, a novel first-in-class anti-resistance therapy for the treatment of gastric, pancreatic, colorectal and other cancers in combination with existing anti-cancer therapies. BOLD-100 has demonstrated synergy in established preclinical models in combination with a wide variety of anti-cancer therapies including both traditional chemotherapies and targeted therapies including tyrosine kinase inhibitors and checkpoint inhibitors.
BOLD-100 successfully completed a Phase 1 monotherapy dose escalation study and was subsequently granted an Orphan Drug Designation (ODD) in pancreatic cancer. Bold Therapeutics next clinical trial with BOLD-100 has been initiated. This Phase 1b trial will investigate BOLD-100 in combination with FOLFOX in patients with advanced gastric, pancreatic, bile duct and colon cancer. Bold Therapeutics will be starting recruitment of patients at various sites in Canada and the United States shortly.Learn More